Business Context and Reporting Period
Company: Intellia Therapeutics, Inc. (NTLA)
Filing Type: Form 8-K (Current Report)
Date of Report: March 2, 2026
Principal Executive Offices: Cambridge, Massachusetts
This filing reports two material events: the amendment of an at-the-market (ATM) equity offering agreement and the lifting of a clinical hold by the U.S. Food and Drug Administration (FDA) on a Phase 3 clinical trial.
Key Financial Metrics and Capital Structure
Equity Offering Program (ATM):
- Previous Cap: $750,000,000
- New Cap (as of March 2, 2026): $1,035,316,650
- Amount Sold to Date: Approximately $635,316,650
- Remaining Capacity under Prior Prospectus: Approximately $114,683,350
- Additional Shares Authorized: Up to $400,000,000 (inclusive of remaining prior capacity)
- Sales Agent: Jefferies LLC
- Commission: Up to 3.0% of gross proceeds
Other Financial Metrics: The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on capital raising and clinical development milestones rather than periodic financial performance.
Material Changes and Clinical Developments
1. Expansion of ATM Program: The Company increased the aggregate offering price of its ATM program by approximately $285.3 million, raising the total limit to over $1.035 billion. This allows for the sale of up to an additional $400 million in shares through Jefferies.
2. FDA Clinical Hold Lifted: On March 2, 2026, the FDA removed the clinical hold on the MAGNITUDE Phase 3 trial for nexiguran ziclumeran ("nex-z") in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The hold was originally imposed on October 29, 2025, following observations of Grade 4 liver transaminases and increased total bilirubin in a patient.
Mitigation Measures Implemented: To resume the trial, the Company aligned with the FDA on the following measures:
- Enhanced monitoring of liver laboratory tests.
- Guidance for short-term steroid treatment if elevated liver transaminases are observed post-dosing.
- Exclusion of patients with certain liver abnormalities.
- Additional exclusion criteria for patients with recent cardiovascular instability or specific ejection fraction issues.
Outlook, Risks, and Management Commentary
Outlook: Management expects to resume enrollment activities in the MAGNITUDE and MAGNITUDE-2 Phase 3 trials following the implementation of mitigation measures. The Company is not obligated to sell shares under the amended ATM agreement and may suspend the offering at any time.
Risks and Contingencies: The filing highlights significant risks, including:
- Uncertainty regarding the safety, tolerability, and efficacy of nex-z.
- Potential for future regulatory holds or rejections.
- Risks related to the Company's reliance on collaborations (e.g., Regeneron Pharmaceuticals, Inc.).
- Intellectual property challenges and third-party IP validity.
- The possibility that preclinical or clinical results will not be predictive of future outcomes.
Investor Verification Checklist
- Verify the specific terms of the amended Sales Agreement (Exhibit 99.1) regarding the new $400 million authorization.
- Review the full text of the press release (Exhibit 99.2) for details on the FDA's specific requirements for the MAGNITUDE trial resumption.
- Monitor upcoming 10-Q or 10-K filings for updated cash position and burn rate following the potential equity sales.
- Track the enrollment progress of the MAGNITUDE and MAGNITUDE-2 trials to assess the effectiveness of the new safety monitoring protocols.
- Confirm the status of the MAGNITUDE-2 trial (ATTRv-PN), as the filing notes the hold was also imposed on this trial, though the press release specifically highlights the lift for MAGNITUDE.